January 29, 2019
Innate Pharma gets faster development of its Sézary syndrome treatment
Innate Pharma will speed up the development of its anti-KIR3DL2 antibody, to treat T-cell lymphoma, as it has been fast tracked by the US FDA, the company said Tuesday.